文献速递浆细胞疾病

POEMS综合征:2026年诊断、风险分层与管理更新

POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management.
PubMed 文献 · Am J Hematol · 2026-07-07

POEMS综合征由潜在浆细胞肿瘤引起,主要标准包括多神经病、克隆性浆细胞病、硬化性骨病变、血管内皮生长因子升高及Castleman病。诊断需3条主要标准(必含多神经病和克隆性浆细胞病)加至少1条次要标准。风险分层基于临床表型,风险因素包括低白蛋白、年龄、胸腔积液、肺动脉高压和eGFR降低。

要点

  • 诊断需3条主要标准(必含多神经病和克隆性浆细胞病)加至少1条次要标准。
  • 风险因素包括低血清白蛋白、年龄、胸腔积液、肺动脉高压和eGFR降低。
  • 局限性浆细胞瘤首选放疗,弥漫性病变需全身治疗;烷化剂和来那度胺为主要药物。

核心结论

  • 及时识别并启动支持治疗和针对浆细胞的治疗可获得最佳结局。

研究设计与样本

  • 综述,总结POEMS综合征的诊断、风险分层和管理更新。

主要发现

  • 主要标准为多神经病、克隆性浆细胞病、硬化性骨病变、血管内皮生长因子升高和Castleman病。
  • 次要特征包括器官肿大、内分泌病、特征性皮肤改变、视乳头水肿、血管外容量负荷增加和血小板增多。
  • 诊断需3条主要标准(必含多神经病和克隆性浆细胞病)加至少1条次要标准。
  • 风险因素包括低血清白蛋白、年龄、胸腔积液、肺动脉高压和eGFR降低。

关键数值与推荐

  • 诊断标准:3条主要标准(必含多神经病和克隆性浆细胞病)加至少1条次要标准。
  • 风险分层基于临床表型而非特定分子标志物。
  • 局限性浆细胞瘤一线治疗为放疗;弥漫性硬化性病变或播散性骨髓受累需全身治疗。
  • 糖皮质激素为暂时性治疗,烷化剂和来那度胺为主要治疗药物。
  • 沙利度胺和硼替佐米有活性,但需权衡加重周围神经病变的风险。

临床怎么用

  • 对疑似POEMS综合征患者,应检查多神经病、克隆性浆细胞病、硬化性骨病变、血管内皮生长因子和Castleman病以明确诊断。
  • 根据临床表型评估风险因素(低白蛋白、年龄、胸腔积液、肺动脉高压、eGFR降低)。
  • 局限性浆细胞瘤首选放疗;弥漫性病变选择全身治疗,优先考虑烷化剂或来那度胺。
  • 使用沙利度胺或硼替佐米时需监测周围神经病变。
  • 达雷妥尤单抗联合方案基于病例系列显示有前景。

局限性

  • 发病机制未完全阐明,风险分层限于临床表型而非分子标志物。
  • 达雷妥尤单抗联合方案的证据基于病例系列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: POEMS syndrome is a life-threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. DIAGNOSIS: The diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyneuropathy and clonal plasma cell disorder, and at least one of the minor criteria. RISK STRATIFICATION: Because the pathogenesis of the syndrome is not well understood, risk stratification is limited to clinical phenotype rather than specific molecular markers. Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced eGFR. RISK-ADAPTED THERAPY: For those patients with a dominant plasmacytoma, first line therapy is irradiation. Patients with diffuse sclerotic lesions or disseminated bone marrow involvement should receive systemic therapy. Corticosteroids are temporizing, but alkylators and lenalidomide are the mainstays of treatment, the former either in the form of low dose conventional therapy or as high-dose conditioning for stem cell transplantation. Thalidomide and bortezomib also have activity, but their benefit needs to be weighed against their risk of exacerbating the peripheral neuropathy. Daratumumab combinations also appear promising based on case series. Prompt recognition and institution of both supportive care measures and therapy directed against the plasma cell result in the best outcomes.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Dispenzieri A. POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2026. PMID: 42411740. doi:10.1002/ajh.70438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。